European Primary Care Cardiovascular Society

Clinically meaningful benefits with GLP-1RA in patients with HFpEF and obesity

3' education - Oct. 9, 2023 - Mikhail Kosiborod, MD - Kansas City, MO, USA

Educational information

This video was recorded during the ESC Congress 2023 in Amsterdam, The Netherlands


Mikhail Kosiborod, MD is a Cardiologist and Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.


This recording was developed under auspices of EPCCS. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of EPCCS.

Read our summary of the STEP HFpEF study

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: